Cochrane group skeptical about latest Roche pledges

Cochrane group skeptical about latest roche pledges
Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

(HealthDay)—Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in BMJ.

Peter Doshi, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, along with colleagues from the Cochrane group, recently corresponded with Roche as part of the 's open data campaign designed to encourage Roche to honor its 2009 commitment to make the full clinical study reports for 10 trials of Tamiflu available for independent review.

Noting that Roche recently pledged to release full clinical study reports as part of the data transparency program, the authors question these new promises. Roche plans to allow researchers access to a secure system, following agreement, rather than the requested independent review. Three of the four advisors chosen to lead Roche's advisory board, which will grant access to data, have recent financial ties to Roche. In addition, there has been no attempt to correct the scientific record following the 2003 Roche-authored paper claiming the opposite of the U.S. conclusion that has not been shown to prevent serious bacterial complications of influenza.

"Despite our repeated requests for those data, has yet to provide even a single full study report," Doshi writes. "We are independent scientists, not regulators. Doing our own analysis, not dictated by others, is key to what makes us independent."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

5 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

5 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

6 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

6 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments